TLR7 and neoplasm: Furthermore, the topical application of imiquimod (a TLR7 activator) associated with the intramuscular administration of a DNA vector containing HPV16 E7 fused to calreticulin increased the recruitment of CD8+ T cells to the genital tract in an orthotopic HPV16 E6/E7 syngeneic tumor model 76.